Shares of Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company developing therapies to treat blood coagulation disorders, made their Nasdaq Global Select Market debut under the ticker "COAG" on May 1, 2026.
The company priced its initial public offering (IPO) of 16.75 million shares at $18 per share.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.